A Model for Dissemination and Independent Analysis of Industry Data
JAMAPublished 12 October 2011Open access
Harlan M. Krumholz, Joseph S. Ross
Citations43
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Current clinical research standards lack sufficiently strong requirements for transparency and availability, and there are no uniform international standards requiring that study protocols, statistical analysis plans, and study results be made available, nor that completed clinical trial data be posted for independent analysis.
Keywords
MathematicsEconomics, Econometrics and FinancePharmacology, Toxicology and Pharmaceutics
BMJReboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials
575 Citations2010Dirk Eyding, M. Lelgemann +7 more
Reboxetine is, overall, an ineffective and potentially harmful antidepressant and Published evidence is affected by publication bias, underlining the urgent need for mandatory publication of trial data.
PLoS MedicineTrial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis
395 Citations2009Joseph S. Ross, Gregory K. Mulvey +3 more
Joseph Ross and colleagues examine publication rates of clinical trials and find low rates of publication even following registration in Clinicaltrials.gov.
BMC Medical Research MethodologyThe strengths and limitations of meta-analyses based on aggregate data
252 Citations2005Gary H. Lyman, Nicole M. Kuderer
IPD offers advantages and, when feasible, should be considered the best opportunity to summarize the results of multiple studies, but the resources, time and cooperation required for such studies will continue to limit their use in many important areas of clinical medicine.
Archives of Internal MedicinePooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data
82 Citations2009Joseph S. Ross
Cumulative pooled analysis of all randomized, placebo-controlled trials demonstrates a trend toward increased cardiovascular risk associated with rofecoxib compared with placebo as early as December 2000, the comparison reaching a P value of .05 by June 2001, nearly 3(1/2) years before the manufacturer's voluntary market withdrawal.
JAMAThe Role of Litigation in Defining Drug Risks
61 Citations2007Aaron S. Kesselheim, Jerry Avorn
The intersections among the civil justice system, the regulatory apparatus, and the science of pharmacoepidemiology, including the effects of those interactions on drug safety research, clinical knowledge, and regulatory policy are defined.
Archives of Internal MedicinePersistence of Cardiovascular Risk After Rofecoxib Discontinuation
16 Citations2010Joseph S. Ross
During a 1-year period of postdrug observation, increased cardiovascular risk associated with rofecoxib use persisted after stopping treatment, which raises concerns about long-term risks incurred by individuals who had taken the drug.